We appreciate Gu's \[[@CR1]\] interest in our study. We apologize and agree with his comment about attributing units to standardized mean difference (SMD). Nevertheless, similar to the SMD, results in mean difference (control -- nebulized) were unaffected by nebulized antibiotics (2.67 days, 95 % confidence interval (CI) --2.89, 8.23 for ICU length of stay (LOS); and 0.70 days, 95 % CI −3.40, 4.80 for mechanical ventilation). However, we strongly disagree with other points raised by the letter.

First, the study protocol was defined a priori \[[@CR2]\]. We disagree that combining observational studies with intervention studies is reserved only for safety evaluation. This topic has been discussed in the literature and combining both types of studies was adequate for our aim \[[@CR3]\]. Furthermore, we presented the main results separating interventional studies from observational studies, thereby allowing the reader to interpret both analyses independently.

Second, both of the studies cited as "case--control studies" \[[@CR1]\] received this denomination in their title and abstract. However, by reading their methods it becomes clear that they are actually matched cohort studies \[[@CR4], [@CR5]\]. Indeed, they matched exposed patients ("nebulized group") to unexposed patients ("no-nebulized group"). A case--control design starts with the outcome (case = "clinical success") and matches them with controls ("clinical failures"). Therefore, our measure of effect was correct \[[@CR5]\]. For exploration, we report the analysis for clinical cure using the odds ratio (OR) (Fig. [1](#Fig1){ref-type="fig"}). The results are unchanged.Fig. 1Forest plot for clinical cure using odds ratios (OR). *P* for overall effect = 0.015. *CI* confidence interval

Third, Kalin's study was included because it fulfilled our inclusion/exclusion criteria \[[@CR2]\]. Gu's suggestion to exclude this study based solely on its effects in heterogeneity could be considered selective reporting \[[@CR1]\].

Our study provided data for further trials aiming to evaluate the effect of nebulized antibiotics in ventilator-associated pneumonia (VAP) \[[@CR2]\].
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:   Confidence interval
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:   Length of stay

OR

:   Odds ratio

SMD

:   Standardized mean difference

VAP

:   Ventilator-associated pneumonia

See related Letter by Gu, <http://www.ccforum.com/content/19/1/236>, and related research by Zampieri et al., <http://ccforum.com/content/19/1/150>.
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